Stammdaten
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Unternehmen & Branche
| Name | Rani Therapeutics Holdings, Inc. |
|---|---|
| Ticker | RANI |
| CIK | 0001856725 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 56,8 Mio. USD |
| Beta | 0,66 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,633,000 | -29,673,000 | -0.45 | 58,621,000 | 33,010,000 |
| 2025-09-30 | 10-Q | 0 | -5,412,000 | -0.12 | 10,139,000 | -7,860,000 |
| 2025-06-30 | 10-Q | 0 | -6,692,000 | -0.18 | 16,898,000 | -5,575,000 |
| 2025-03-31 | 10-Q | 172,000 | -7,264,000 | -0.22 | 24,125,000 | -3,056,000 |
| 2024-12-31 | 10-K | 1,028,000 | -30,018,000 | -1.05 | 36,634,000 | 1,992,000 |
| 2024-09-30 | 10-Q | 0 | -6,783,000 | -0.24 | 43,540,000 | 3,120,000 |
| 2024-06-30 | 10-Q | 0 | -6,805,000 | -0.26 | 43,726,000 | 2,835,000 |
| 2024-03-31 | 10-Q | 0 | -7,483,000 | -0.29 | 53,512,000 | 7,398,000 |
| 2023-12-31 | 10-K | 0 | -33,970,000 | -1.33 | 57,916,000 | 12,866,000 |
| 2023-09-30 | 10-Q | -9,197,000 | -0.36 | 70,436,000 | 17,553,000 | |
| 2023-06-30 | 10-Q | -9,303,000 | -0.37 | 83,507,000 | 24,094,000 | |
| 2023-03-31 | 10-Q | -8,372,000 | -0.33 | 96,446,000 | 30,722,000 | |
| 2022-12-31 | 10-K | 0 | -30,588,000 | -1.28 | 108,027,000 | 36,855,000 |
| 2022-09-30 | 10-Q | 0 | -7,955,000 | 0.33 | 108,202,000 | 42,194,000 |
| 2022-06-30 | 10-Q | 0 | -7,624,000 | 0.31 | 104,344,000 | 47,813,000 |
| 2022-03-31 | 10-Q | -6,223,000 | 0.29 | 115,309,000 | 53,384,000 | |
| 2021-12-31 | 10-K | 2,717,000 | -8,331,000 | -0.43 | 124,207,000 | 47,411,000 |
| 2021-09-30 | 10-Q | 0 | -3,142,000 | -0.16 | 136,958,000 | 51,366,000 |
| 2021-06-30 | 10-Q | 1,961,000 | -5,485,000 | 77,321,000 | ||
| 2021-03-31 | 10-Q | 756,000 | -5,598,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-23 | IMRAN MIR A | Director, 10% Owner | Open Market Purchase | 2,083,334 | 0.61 | 1,260,417.07 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.